Major award for world-leaders in melanoma research
9 November 2018
Melanoma Institute Australia’s (MIA) Co-Medical Directors have won the prestigious GSK Award for Research Excellence at Research Australia’s Health and Medical Research Awards.
Professor Georgina Long and Professor Richard Scolyer have been recognised as world leaders in melanoma research for their ground-breaking work that has changed the diagnosis and treatment landscape of melanoma world-wide, and tripled the life-expectancy of advanced melanoma patients.
Professor Long and Professor Scolyer believe that with the advancement of both immune- and targeted therapies (those treatments that utilise patients’ immune systems to fight cancer or alter the function of specific genes to arrest the growth of cancer) we are now realistically looking towards achieving zero deaths from melanoma within their lifetimes.
“As Australians, we’re proud of the success our country has had in leading the fight against melanoma but there’s still much more to do and discover. There’s a critical need to better understand why some melanomas develop so we can improve prevention and treatment,” said Professor Scolyer.
“While we do have these breakthrough therapies, there are still a group of patients who are resistant,” added Professor Long. “We’re starting to understand why patients develop resistance – and if we can tackle this by individualising and targeting therapy, we will impact not only melanoma but all cancers.”
Professor Long and Professor Scolyer said that winning the GSK Award for Research Excellence highlights the importance of recognising Australian successes in the research space, and is testament to the power of collaboration that MIA strives to emphasise in its work.
“Collaboration is vital for big research steps and gains. For us, this award recognises not only our team, but the collaborative efforts of our predecessors, colleagues, industry and patients,” said Professor Long. “We stand on the shoulders of others’ foresight and hard work, as well as the generosity of Australian patients whose participation in clinical trials is critical to scientific discovery.”
“It’s important that Australian science and research success is celebrated, and we are grateful to be a part of that story. We are honoured and humbled to have received this award as we, and our team, work hard to impact the lives of patients all over the world,” said Professor Scolyer.
Dr. Andrew Weekes, Medical Director of GSK, said; “The work of Professors Long and Scolyer is an outstanding example of how home-grown innovation and collaboration can impact the lives of patients around the world. We are honoured to recognise their achievements and support research which could underpin further discoveries and better outcomes for patients.”
The GSK Award for Research Excellence is one of the most prestigious awards available to the Australian medical research community. It has been awarded since 1980 to recognise outstanding achievements in medical research with potential importance to human health.
The GSK Award comes just a week after MIA’s Co-Medical Directors, and their fellow researchers Associate Professor Alex Menzies and Associate Professor Anne Cust, received top awards at the NSW Premier’s Awards for Outstanding Cancer Research.
It’s time again to say thank you to our amazing community fundraisers!
Videos of the sessions at the recent Patient Information Evening co-hosted by Melanoma Institute Australia (MIA) and Melanoma Patients Australia (MPA) are now available for viewing.
MIA is well-represented in the poster sessions at the Society for Melanoma Research 2019 Congress in the USA, with four poster presentations being given by members of our translational research lab.
Professor Georgina Long has today opened the Society for Melanoma Research 2019 Congress in Salt Lake City, Utah.
MIA’s Co-Medical Directors, Professor Georgina Long and Professor Richard Scolyer, have both been named Highly Cited Researchers, according to the Clarivate Analytics Highly Cited Researchers 2019 list.
Melanoma Patients Australia (MPA) and Melanoma Institute Australia (MIA) have announced a new multi-year agreement to provide enhanced support services for melanoma patients nationally.
It is time again to say thank you to our incredible community fundraisers who are helping us get closer to our goal of zero deaths from melanoma.
MIA has presented promising data regarding progression-free survival rates for advanced melanoma patients at the ESMO 2019 Congress in Barcelona.
Another month has flown by and yet again we have a host of amazing community fundraisers who generously gave up their time to help us reach our goal of zero deaths from melanoma.
Comments in favour of giving patients with BRAF-positive melanoma access to first-line immunotherapy need to be submitted online prior to October 9, 2019.
Jay's Longest Melanoma March documentary is screening this Sunday 22 September at 1pm (AEST) on Channel 10, capturing behind the scenes of the 2000km walk, Adelaide to Sydney in 50 days. Uniting to end melanoma.
It’s been a month since we highlighted some of our incredibly generous community fundraisers. We thought we’d have a look back at August and put the spotlight on more of the wonderful people who give up their time to fundraise for MIA, so we can continue to edge closer to our goal of zero deaths from melanoma.
They are a formidable team - in work and in play
This week, Melanoma Institute Australia hosted the first of six
Federal government urged
We want to thank every member of Team Melanoma and everyone who donated to them. With your help, we are moving closer to our goal of zero deaths from melanoma!
Lauren O'Brien tells us why she's running for a cause close to her heart
MIA could not do what we do without the incredible support and effort of our community fundraisers. We’d like to highlight some of the wonderful events organised by our community in